International Journal of Cardiology
Volume 129, Issue 3 , Pages 379-387, 13 October 2008

Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study☆☆

  • Gilles Montalescot

      Affiliations

    • Institut de Cardiologie, Pitié-Salpêtrière Hospital, Paris, France
    • Corresponding Author InformationCorresponding author. Gilles Montalescot, Institut de Cardiologie, Bureau 2-236, Centre Hospitalier Universitaire Pitié-Salpêtrière, 47 Blvd de l'Hôpital, 75013, Paris, France. Tel.: +33 1 42 16 30 06; fax: +33 1 42 16 29 31.
  • ,
  • Zeki Öngen

      Affiliations

    • Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey
  • ,
  • Ramez Guindy

      Affiliations

    • Cairo Special Hospital, Cairo, Egypt
  • ,
  • Amanda Sousa

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
  • ,
  • Shu-Zheng Lu

      Affiliations

    • Beijing Anzhen Hospital, Beijing, PR China
  • ,
  • Dev Pahlajani

      Affiliations

    • Kirti Manor, Breach Candy Hospital, Mumbai, India
  • ,
  • André Pellois

      Affiliations

    • sanofi-aventis, Paris, France
  • ,
  • Eric Vicaut

      Affiliations

    • Unité de Recherche Clinique, Hôpital Lariboisière, Paris, France
  • ,
  • for the RIVIERA Investigators

Received 26 February 2007; received in revised form 7 June 2007; accepted 7 July 2007. published online 06 December 2007.

Abstract 

Background

Limited information is available about clinical outcomes following routine percutaneous coronary intervention (PCI) in the current era. This study aimed to identify predictors of adverse clinical or angiographic complications following PCI in patients from many different countries.

Methods

RIVIERA is a multinational, prospective, observational study in patients undergoing elective or primary PCI. Consecutive patients (n=7962) were enrolled in 144 hospitals from 23 countries in four different continents. Primary outcome was death or myocardial infarction (MI).

The mean age of the patients was 59 years and 77% were men; 92% of patients underwent elective and 8% primary PCI.

Results

The rate of in-hospital outcomes was low: death 0.3%, MI 1%, any bleeding 3.4%. Angiographic complications occurred in 8.7% of patients, mainly coronary dissection (3.7%) and no reflow (2%). After multivariable analysis, the strongest independent predictors of death or MI were clinical presentation with non-ST-segment elevation acute coronary syndrome or ST-segment elevation myocardial infarction and administration of a glycoprotein (GP) IIb/IIIa inhibitor. Radial access, thienopyridine pretreatment and anticoagulation with enoxaparin were associated with a lower risk of death or MI. Female gender, PCI of coronary artery bypass graft, administration of a GP IIb/IIIa inhibitor and combined use of enoxaparin and unfractionated heparin were significantly associated with more bleeding. Radial access was the only variable associated with less bleeding.

Conclusions

Routine PCI appears to be a relatively safe revascularization procedure. Many of the variables identified as predictors of adverse cardiac outcomes confirm results obtained in recent randomized PCI trials and are modifiable, suggesting that further improvements can be made.

Keywords: Angiographic complications, Angioplasty, Myocardial infarction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Grant support: The RIVIERA study is funded by sanofi-aventis, Paris, France.

☆☆ The authors all served on the advisory board of the RIVIERA registry. In addition, Gilles Montalescot has received research grants from sanofi-aventis, Eli Lilly and Guerbet; honoraria from sanofi-aventis, Eli-Lilly, GSK, MSD, The Medicine's Company, and Pfizer, and has been consulted/on advisory boards for sanofi-aventis, Eli-Lilly, GSK, MSD, The Medicine's Company, Schering Plough, and Pfizer; Andre Pellois was an employee of sanofi-aventis; Amanda Sousa had received enoxaparin.

PII: S0167-5273(07)01714-7

doi:10.1016/j.ijcard.2007.07.127

International Journal of Cardiology
Volume 129, Issue 3 , Pages 379-387, 13 October 2008